Drug (ID: DG00182) and It's Reported Resistant Information
Name
Spiramycin
Synonyms
Spiramycin; 8025-81-8; ST075006; Spiramycinum; Spiramycine; Provamycin; Sequamycin; Espiramicin; Rovamycin; Antibiotic 799; NSC-64393; RP 5337; Rovamycine; Prestwick_121; 5337 R.P.; Prestwick2_000745; Prestwick3_000745; AC1O4WG0; Spiramycin antibiotic complex; BPBio1_000804; SCHEMBL5032756; AKOS015896378; K430; SR-01000872632; SR-01000872632-1; I06-1973; Spiramycin, European Pharmacopoeia (EP) Reference Standard; Spiramycin from Streptomyces sp., VETRANAL(TM), analytical standard; Spiramycin, Pharmaceutical Secondary Standard
    Click to Show/Hide
Indication
In total 1 Indication(s)
Bacterial infection [ICD-11: 1A00-1C4Z]
Approved
[1], [2], [3], [4], [5]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (4 diseases)
Bacillus infection [ICD-11: 1C4Y]
[6]
Bacterial infection [ICD-11: 1A00-1C4Z]
[1], [2], [3]
Mycobacterial diseases [ICD-11: 1B2Z ]
[7]
Streptococcal pharyngitis [ICD-11: 1B51]
[8]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (2 diseases)
Actinomycetoma [ICD-11: 1C43]
[9]
Bacterial infection [ICD-11: 1A00-1C4Z]
[10]
Target Bacterial 23S ribosomal RNA (Bact 23S rRNA) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C43H74N2O14
IsoSMILES
C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C
InChI
1S/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26 ,27 ,28 ,29+,30 ,31-,32+,34 ,35 ,36 ,37 ,38 ,39+,40+,41 ,42 ,43 /m1/s1
InChIKey
ACTOXUHEUCPTEW-JMRHEKERSA-N
PubChem CID
6419898
TTD Drug ID
D0F5OR
DrugBank ID
DB06145
Type(s) of Resistant Mechanism of This Drug
  ADTT: Aberration of the Drug's Therapeutic Target
  DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Click to Show/Hide the Resistance Disease of This Class
Bacterial infection [ICD-11: 1A00-1C4Z]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: ErmR rRNA adenine N6-methyltransferase (ERMR) [10]
Molecule Alteration Expression
Inherence
Resistant Disease Aeromicrobium erythreum infection [ICD-11: 1A00-1C4Z]
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model Aeromicrobium erythreum strains AR18 2041
Aeromicrobium erythreum strains AR1807 2041
Aeromicrobium erythreum strains AR1848 2041
Aeromicrobium erythreum strains AR1849 2041
Aeromicrobium erythreum strains AR1850 2041
Aeromicrobium erythreum strains BD170 2041
Experiment for
Molecule Alteration
Southern blotting assay
Experiment for
Drug Resistance
Disk diffusion assay
Mechanism Description Using the Ery- strain AR1807 as a recipient for plasmid-directed integrative recombination, the chromosomal ermR gene (encoding 23S rRNA methyltransferase) was disrupted, ermR-disrupted strains AR1848 and AR1849 were highly sensitive to erythromycin and the other macrolide antibiotics. Phenotypic characterizations demonstrated that ermR is the sole determinant of macrolide antibiotic resistance in A. erythreum. AR18, AR1807, and AR1850 (Ery- Ermr) were resistant to clindamycin, erythromycin, spiramycin, and tylosin (some sensitivity totylosin was observed at high concentrations).
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: Macrolide 2'-phosphotransferase II (MPHB) [1], [2], [3]
Molecule Alteration Expression
Up-regulation
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli AG100A 562
Escherichia coli DB10 562
Escherichia coli TOP10 83333
Escherichia coli XL1-Blue 562
Staphylococcus aureus RN4220 1280
Experiment for
Molecule Alteration
Whole genome sequence assay
Experiment for
Drug Resistance
Agar dilution method assay
Mechanism Description Mph enzymes inactivate macrolides by phosphorylating the 2'-OH of the essential dimethylamino sugar, preventing it from binding the ribosome, and providing the chemical rationale for the resistance phenotype.
Mycobacterial diseases [ICD-11: 1B2Z ]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: 23S ribosomal RNA methyltransferase Erm (ERM39) [7]
Molecule Alteration Missense mutation
Putative initiation codon GTG>CTG
Resistant Disease Mycobacterium fortuitum infection [ICD-11: 1B2Z.2]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Mycobacterium peregrinum ATCC14467 43304
Experiment for
Molecule Alteration
DNA sequencing assay
Experiment for
Drug Resistance
Mueller-Hinton (MH) broth assay
Mechanism Description The erm genes are a diverse collection of methylases that add one or two methyl groups to the adenine at position 2058 (Escherichia coli numbering) of the 23S rRNA; this modification impairs the binding of macrolides to ribosomes, and thus reduces the inhibitory activity of these agents.
Streptococcal pharyngitis [ICD-11: 1B51]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: Macrolide-lincosamide-streptogramin B resistance protein (ERMA) [8]
Molecule Alteration Methylation
Macrolide-binding site on the ribosome
Resistant Disease Streptococcus pyogenes infection [ICD-11: 1A00-1C4Z]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli AG100A 562
Experiment for
Molecule Alteration
PCR amplification and sequence alignments assay
Experiment for
Drug Resistance
Agar dilution method assay
Mechanism Description Macrolide resistance commonly occurs due to methylation of the macrolide-binding site on the ribosome by methyltransferases encoded by the erm group of genes, Induction of erm(A) occurs by translational attenuationInduction of erm(A) occurs by translational attenuation.
Actinomycetoma [ICD-11: 1C43]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Key Molecule: srmA open reading frame gimA (GIMA) [9]
Molecule Alteration Expression
Inherence
Resistant Disease Streptomyces ambbyaciens infection [ICD-11: 1C43.0]
Experimental Note Discovered Using In-vivo Testing Model
In Vitro Model Escherichia coli 668369
Escherichia coli strain S17.1 1227813
Micrococcus luteus strain Cgr 1270
Micrococcus luteus strain DSM1790 1270
Streptomyces ambofaciens strain ATCC 23877 278992
Streptomyces ambofaciens strain OS41.99 1954
Streptomyces ambofaciens strain OS41.99NP 1954
Streptomyces ambofaciens strain OS81 1954
Streptomyces lividans strain OS456 1916
Experiment for
Molecule Alteration
DNA sequencing assay
Experiment for
Drug Resistance
Observation of growth inhibition zones assay
Mechanism Description With UDP-[14C]glucose as the cofactor, crude S30 extracts from OS456(pOS41.90) were tested on various macrolides. Among those, chalcomycin was the most active substrate. Methymycin, tylosin, pikromycin, and rosaramicin were four of the best substrates. Oleandomycin, josamycin, and carbomycin were glycosylated to a lesser extent. Macrolides that were found to be as poor substrates of GimA as lankamycin were erythromycin and angolamycin. Spiramycin was also a very poor substrate.
Bacillus infection [ICD-11: 1C4Y]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: 23S ribosomal RNA methyltransferase Erm34 (ERM34) [6]
Molecule Alteration Methylation
Ribosomal methylation
Resistant Disease Bacillus clausii infection [ICD-11: 1C4Y.1]
Experimental Note Identified from the Human Clinical Data
In Vitro Model Bacillus clausii ATCC 21536 79880
Experiment for
Molecule Alteration
Cloning experiments and gene seqencing assay
Experiment for
Drug Resistance
Agar dilution assay
Mechanism Description This pattern of resistance generally due to the presence of an erm gene encoding a ribosomal methylase.
References
Ref 1 Purification and characterization of macrolide 2'-phosphotransferase type II from a strain of Escherichia coli highly resistant to macrolide antibiotics. FEMS Microbiol Lett. 1992 Oct 1;76(1-2):89-94. doi: 10.1016/0378-1097(92)90369-y.
Ref 2 Resistance phenotypes conferred by macrolide phosphotransferases. FEMS Microbiol Lett. 2007 Apr;269(2):317-22. doi: 10.1111/j.1574-6968.2007.00643.x. Epub 2007 Feb 16.
Ref 3 The evolution of substrate discrimination in macrolide antibiotic resistance enzymes. Nat Commun. 2018 Jan 9;9(1):112. doi: 10.1038/s41467-017-02680-0.
Ref 4 Cloning and nucleotide sequence of the mphB gene for macrolide 2'-phosphotransferase II in Escherichia coli. FEMS Microbiol Lett. 1996 Nov 1;144(2-3):197-202. doi: 10.1111/j.1574-6968.1996.tb08530.x.
Ref 5 Expression of the mphB gene for macrolide 2'-phosphotransferase II from Escherichia coli in Staphylococcus aureus. FEMS Microbiol Lett. 1998 Feb 15;159(2):337-42. doi: 10.1111/j.1574-6968.1998.tb12880.x.
Ref 6 Characterization of a new erm-related macrolide resistance gene present in probiotic strains of Bacillus clausii. Appl Environ Microbiol. 2004 Jan;70(1):280-4. doi: 10.1128/AEM.70.1.280-284.2004.
Ref 7 Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005 Feb;55(2):170-7. doi: 10.1093/jac/dkh523. Epub 2004 Dec 8.
Ref 8 Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A). J Antimicrob Chemother. 2009 Jan;63(1):42-6. doi: 10.1093/jac/dkn432. Epub 2008 Oct 24.
Ref 9 Characterization of a glycosyl transferase inactivating macrolides, encoded by gimA from Streptomyces ambofaciens. Antimicrob Agents Chemother. 1998 Oct;42(10):2612-9. doi: 10.1128/AAC.42.10.2612.
Ref 10 Cloning vectors, mutagenesis, and gene disruption (ermR) for the erythromycin-producing bacterium Aeromicrobium erythreum. Appl Environ Microbiol. 1991 Sep;57(9):2758-61. doi: 10.1128/aem.57.9.2758-2761.1991.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.